Company Overview
Milestone Scientific Inc. operates as a biomedical technology company dedicated to the patenting, designing, development, and commercialization of diagnostic and therapeutic injection technologies alongside devices for medical and dental applications. The firm serves the healthcare sector within the medical instruments and supplies industry, focusing its operations on the United States, China, and international markets through its Dental and Medical segments. The company maintains a small-scale operation with a market capitalization of $20.92M, an annual revenue of $8.93M over the trailing twelve months, and an employee base of 17 individuals. These valuation and revenue figures indicate that Milestone Scientific functions as a micro-cap entity with a relatively narrow operational footprint compared to larger peers in the medical device space. The limited number of employees suggests a lean organizational structure typical of early-stage technology firms, while the market cap reflects a valuation that is sensitive to market sentiment regarding its specific niche in injection technologies.
Financial Health
Milestone Scientific reported total revenue of $8.93M for the trailing twelve months, yet it recorded a net income loss of $6,667,190 and an EBITDA of $-6,591,487, revealing a significant structural gap where operating costs and expenses substantially exceed gross profit generation. This disparity between positive revenue and negative net income highlights a cost structure characterized by high burn rates, likely driven by research and development expenditures or sales and marketing costs required to penetrate the medical and dental markets. The company generated free cash flow of $-1,622,917, indicating a net cash outflow that limits its financial flexibility and necessitates ongoing capital raising or existing cash reserves to fund operations without external dilution. Analyzing the margin profile shows a gross margin of 71.9%, which suggests efficient production or high pricing power on core products, contrasted sharply by an operating margin of -48.1% and a profit margin of -74.7% that underscore the intensity of overhead expenses eroding profitability. Regarding liquidity and leverage, the company holds $1.35M in cash against $1.05M in debt, resulting in a debt-to-equity ratio of 41.33, which points to a balance sheet that is leveraged but currently supported by positive cash on hand. The current ratio stands at 1.61, indicating that the company possesses sufficient current assets to cover its short-term liabilities with a comfortable buffer above the standard 1.5 threshold. Furthermore, the return on equity is -136.5% and the return on assets is -42.3%, metrics that reveal management is currently generating negative returns on the capital invested by shareholders and creditors rather than creating value through profitable operations.
Valuation Assessment
The trailing twelve-month P/E ratio is not available due to the lack of earnings, while the forward P/E is listed as -4.43, implying that the market expects earnings to remain negative or that the valuation metric is distorted by the company's loss-making status. The price-to-book ratio is 8.31, which indicates that the market is pricing the company at a significant premium over its book value, suggesting high expectations for future growth or asset appreciation despite current losses. Alternative valuation metrics such as the price-to-sales ratio of 2.34 and an EV/EBITDA of -3.13 suggest that investors are valuing the firm primarily on its revenue generation capabilities rather than current profitability or cash flow generation. Milestone Scientific trades between a 52-week high of $1.11 and a 52-week low of $0.22; without a specific current share price provided in the facts, the valuation is inherently volatile within this range where the stock can fluctuate significantly from its recent highs and lows. The stock exhibits a beta of 0.94, which means its price volatility moves in tandem with the broader market, showing slightly less sensitivity to market swings than the average stock. These valuation multiples combined with the negative earnings picture create a complex valuation environment where traditional profitability-based metrics are less relevant than revenue growth potential or asset backing.
Growth & Income
The company experienced a revenue growth rate of -6.1% year-over-year, while the earnings growth rate is not applicable due to the absence of positive earnings to measure against prior periods, implying that the firm is in a contractionary phase regarding top-line sales rather than an expansionary growth phase. As the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it does not distribute cash to shareholders but instead retains all earnings, or rather losses, to reinvest into its product development and commercialization efforts. This lack of dividend payout aligns with the strategic necessity for loss-making biotech and medtech firms to conserve cash for R&D and market expansion rather than providing income to investors. Consequently, the overall growth and income profile of Milestone Scientific is defined by revenue contraction and a reliance on internal capital reserves or external financing to sustain operations in the absence of dividend income or positive earnings growth.